Genomic profiling of prostate cancer in Native American men

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The study will enroll patients who self-identify as Native American and have a confirmed diagnosis of prostate cancer, collecting archived tumor tissue and a blood sample within the first year of enrollment. Researchers will perform whole exome sequencing (WES) and whole transcriptome sequencing (RNA-seq) to map genomic and transcriptomic features of the tumors. Data will be assembled into a comprehensive database with oversight from a Tribal Institutional Review Board and a Community Advisory Board to ensure cultural appropriateness and community engagement. The initiative begins at OU Health Stephenson Cancer Center with planned expansion to additional sites across Oklahoma and later to other U.S. institutions to broaden representation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Written informed consent signed and dated by the patient prior to the performance of any study-specific procedures, sampling, or analyses.
* At least 18 years-of-age at the time of signature of the informed consent form (ICF).
* Patients who self-identify as Native American.
* Patients with a pathologically proven diagnosis of PC and RCC (any stage).
* Availability of most recent archived tumor samples.

Exclusion Criteria:

* Patients not of Native American descent or identity.
* Patient does not have archival tissue available.

Where it's running

• OU Health Stephenson Cancer Center
  Oklahoma City, Oklahoma, United States Recruiting

Study contacts

• Principal investigator: Adanma Ayanambakkam, MD, MS — University of Oklahoma
• Study coordinator: Lead Onco Nurse
• Email: SCC-IIT-Office@ouhsc.edu
• Phone: 405-271-8777

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer

  This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.

  Recruiting Niguarda Hospital · Milan, Lombardy · NCT07879820

• Nectin-4 PET/CT imaging to differentiate renal tumors

  This study tests a new PET tracer, 18F-N230A, to see if it helps distinguish renal cell carcinoma from renal pelvic urothelial carcinoma in adults.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT07875959

• Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer

  This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.

  Recruiting Lithuanian University of Health Sciences · Kaunas · NCT07863986

• Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer

  This observational study tests whether salvage HDR brachytherapy can help men with locally recurrent prostate cancer after initial radiotherapy, using advanced imaging and biopsy to guide treatment.

  Recruiting at 8 sites Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic · Benidorm, Alicante and 9 other locations · NCT07860528

• Multi-peptide Vaccination and PSMAxCD3 Antibody Therapy for Prostate Cancer with Biochemical Recurrence

  This phase 2 trial tests whether a PSMA-targeted bispecific antibody (CC-1), a prostate cancer peptide vaccine (VAC-XS15-PC01), or both can be given safely and help control biochemical recurrence after local therapy in men with prostate cancer.

  Recruiting Phase 2 University Hospital Tuebingen · Heidelberg, Baden-Wurttemberg and 3 other locations · NCT07860047

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.